CATALOGO DEI PRODOTTI DELLA RICERCA

PERTILE, Paolo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.525
NA - Nord America 1.462
AS - Asia 494
AF - Africa 13
SA - Sud America 3
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.500
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.456
GB - Regno Unito 483
IT - Italia 354
CN - Cina 343
RU - Federazione Russa 131
FR - Francia 112
IE - Irlanda 109
SE - Svezia 108
SG - Singapore 94
FI - Finlandia 89
DE - Germania 85
UA - Ucraina 19
BE - Belgio 11
VN - Vietnam 11
ID - Indonesia 9
TG - Togo 9
KR - Corea 8
CZ - Repubblica Ceca 6
TR - Turchia 6
CA - Canada 5
HK - Hong Kong 5
IR - Iran 5
AT - Austria 3
DK - Danimarca 3
ES - Italia 3
IN - India 3
SY - Repubblica araba siriana 3
UG - Uganda 3
AU - Australia 2
CH - Svizzera 2
CO - Colombia 2
GR - Grecia 2
JO - Giordania 2
JP - Giappone 2
AL - Albania 1
BR - Brasile 1
EG - Egitto 1
EU - Europa 1
HU - Ungheria 1
KZ - Kazakistan 1
MT - Malta 1
MX - Messico 1
NL - Olanda 1
NO - Norvegia 1
PK - Pakistan 1
SA - Arabia Saudita 1
Totale 3.500
Salva come PNG Salva come JPEG
Città #
Southend 437
Chandler 308
Woodbridge 198
Jacksonville 162
Ann Arbor 161
Dublin 109
Verona 84
Ashburn 83
Singapore 69
Padova 53
Beijing 51
Princeton 46
Lawrence 44
Wilmington 41
Houston 36
Nanjing 31
Helsinki 29
Milan 28
Shenyang 27
Jinan 23
Tianjin 21
Boardman 16
Hebei 14
Lancaster 14
Zhengzhou 14
Sindelfingen 13
Taiyuan 13
Brussels 11
Haikou 11
Guangzhou 10
Ningbo 10
Dallas 9
Jakarta 9
Lomé 9
Norwalk 9
Redmond 9
Roverbella 9
Taizhou 9
Hangzhou 8
Jiaxing 8
Los Angeles 8
Afragola 7
Changsha 7
Dong Ket 7
Nanchang 7
New York 7
Belluno 6
Rome 6
Romola 6
Seattle 6
Dearborn 5
Hong Kong 5
Lanzhou 5
San Giovanni Lupatoto 5
Washington 5
Auburn Hills 4
Fairfield 4
Garbagnate Milanese 4
Lonigo 4
Monteforte d'Alpone 4
Moscow 4
Redwood City 4
Reggio Calabria 4
Santa Clara 4
Tappahannock 4
Trento 4
Vicenza 4
Braunschweig 3
Falls Church 3
Lungavilla 3
Maple 3
Orani 3
Paese 3
Pisa 3
San Francisco 3
Seoul 3
Vienna 3
Vigo 3
Wuhan 3
Yangcheon-gu 3
Amman 2
Ankara 2
Biebesheim 2
Bogotá 2
Bolzano 2
Brescia 2
Cambridge 2
Chions 2
Clearwater 2
Cologne 2
Copenhagen 2
Dongguan 2
Düsseldorf 2
Esslingen am Neckar 2
Florence 2
Foligno 2
Genoa 2
Hyderabad 2
Ilmenau 2
Kent 2
Totale 2.465
Salva come PNG Salva come JPEG
Nome #
A Large Scale OLG Model for the Analysis of the Redistributive Effects of Policy Reforms 138
Public policies over the life cycle: a large scale OLG model for France, Italy and Sweden 134
Free-Riding in Pharmaceutical Price Regulation: Theory and Evidence 134
R&D and market size: who benefits from orphan drug regulation? 127
Redistribution at the Local Level: The Case of Public Childcare in Italy. University of Verona Department of Economics Working Paper 21/2013 (ISSN 2036-2919) 121
A large scale OLG model for France, Italy and Sweden: assessing the interpersonal and intrapersonal redistributive effects of public policies 110
Redistribution at the Local Level: The Case of Public Childcare in Italy 104
Public finance consolidation and fairness across living generations: the case of Italy. WP Series University of Verona Department of Economics (ISSN 2036-2919), 04/2012 100
L'ISEE in Italia: una nota metodologica partendo dai dati EU-SILC. University of Verona Department of Economics Working Paper 6/2014 (ISSN 2036-2919) 96
The dynamics of pharmaceutical regulation and R&D investments. WP Series University of Verona Department of Economics (ISSN 2036-2919), 4/2012 91
DRGs: the link between investment in technologies and appropriateness. WP Series University of Verona Department of Economics (ISSN 2036-2919), 31/2012 85
Late-Stage Pharmaceutical R&D and Pricing Policies under Two-Stage Regulation 83
A Bayesian Decision-Theoretic Model of Sequential Experimentation with Delayed Response 82
Dynamic, economic approaches to HTA under uncertainty. WP Series University of Verona Department of Economics (ISSN 2036-2919), 03/2011 79
Who should monitor job sick leave? 79
The dynamics of pharmaceutical regulation and R&D investments 79
Optimal Decision Rules for HTA Under Uncertainty: a Wider, Dynamic Perspective 78
Two-part payments for the reimbursement of investments in health technologies 74
Should current criteria for detecting and repairing arteriovenous fistula stenosis be reconsidered? Interim analysis of a randomized controlled trial 74
Late-Stage Pharmaceutical R&D and Pricing Policies under Two-Stage Regulation 73
Drug Prices and Incentives to Innovation by the Pharmaceutical Industry 72
Optimal sequential sampling rules for the economic evaluation of health technologies 71
The fiscal disadvantage of young italians: a new view on consolidation and fairness 71
Optimal Bayesian sequential sampling rules for the economic evaluation of health technologies 70
The timing of adoption of positron emission tomography:a real options approach 70
Job Sick Leave: Detecting Opportunistic Behavior 69
An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography 67
Pricing policies when patients are heterogeneous: a welfare analysis 67
Technology adoption, quality and health care costs: a review of the literature 66
A Bayesian Decision-Theoretic Model of Sequential Experimentation with Delayed Response 66
Investment in health technologies in a competitive model with real options 65
Spillovers of Pharmaceutical Price Regulations: evidence from the AMNOG Reform in Germany 62
Is chest X-ray screening for lung cancer in smokers cost-effective? Evidence from a population-based study in Italy 60
Static and dynamic effciency of irreversible health care investments under alternative payment rules 59
Public health interventions: evaluating the economic evaluations 57
The impact of managed entry agreements on pharmaceutical prices 57
L’equità intergenerazionale delle politiche di bilancio 55
A reply to "Who would benefit from average value-based pricing?" 55
Static and Dynamic Efficiency of Irreversible Health Care investments under Alternative Payment Rules 51
R&D and market size: who benefits from orphan drug legislation? 51
Cost-effective clinical trial design: Application of a Bayesian sequential model to the ProFHER pragmatic trial 46
Authors' Reply to Garattini and Freemantle: "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition" 43
Optimal Sequential Sampling with Delayed Observations and Unknown Variance 43
Efficienza e sostenibilità dell’intervento pubblico 39
Which valued-based price when patients are heterogeneous? 33
Improving access to medicines and promoting pharmaceutical innovation 31
Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition 28
Investimenti pubblici, risorse scarse: il ruolo dei diversi metodi di supporto alle decisioni 27
A stepped-wedge randomised controlled trial to assess efficacy and cost-effectiveness of a care-bundle to prevent falls in older hospitalised patients 24
Valutare l’efficienza dei servizi ospedalieri in Italia: il caso delle aziende ospedaliero-universitarie 21
Strategic Interaction in Pharmaceutical Price Regulation: With or Without U? 18
Dynamic, incentive-compatible contracting for health services 18
Totale 3.573
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.820
article - articoli 6.670
book - libri 0
conference - conferenze 220
curatela - curatele 204
other - altro 4.945
patent - brevetti 0
selected - selezionate 0
volume - volumi 781
Totale 25.640
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020244 0 0 0 24 19 30 70 15 7 35 16 28
2020/2021372 48 69 10 51 40 32 6 18 40 13 26 19
2021/2022422 30 70 13 6 19 17 18 25 41 13 66 104
2022/2023804 60 96 72 122 76 194 7 53 84 12 24 4
2023/2024435 18 30 31 72 47 57 27 38 10 16 53 36
2024/2025307 57 90 67 93 0 0 0 0 0 0 0 0
Totale 3.573